Compare Dicks Sporting Goods Inc (DKS) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Inovio Pharmaceuticals Inc — how do they compare? Dicks Sporting Goods Inc trades at $202.53 (market cap $18.35B), while Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M). The key difference: Dicks Sporting Goods Inc is far larger — about 233.6× Inovio Pharmaceuticals Inc's market cap, and Dicks Sporting Goods Inc pays a 2.44% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| DKS | INO | |
|---|---|---|
Market Cap | $18.35B | $78.55M |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $2.87 |
52-Week Low | $187.78 | $0.66 |
Enterprise Value | $25.14B | $49.56M |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DKS trades at $203.44, down 4.98% on the day, amid a bearish technical signal. The company has consistently beaten earnings estimates in recent quarters, with strong profitability metrics including a 20.9% ROE and 4.71% net income margin. Analyst consensus is strongly bullish with a $263.22 price target and no sell ratings. Recent news highlights include positive coverage from Zacks and an upcoming Q2 2026 earnings call on August 25th.
The outlook remains positive given strong fundamentals and analyst support, but risks include competitive pressures and the stock's current bearish technical trend. The key near-term catalyst is the Q2 earnings report, which could validate the bullish sentiment if results meet or exceed the expected EPS of $3.77.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
